{"protocolSection":{"identificationModule":{"nctId":"NCT01263691","orgStudyIdInfo":{"id":"EBS.AVA.201 / DMID 10-0013"},"secondaryIdInfos":[{"id":"HHSN272200800051C","type":"OTHER_GRANT","domain":"BARDA/NIAID"}],"organization":{"fullName":"Emergent BioSolutions","class":"INDUSTRY"},"briefTitle":"Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults","officialTitle":"A Parallel-arm, Double-blind, Randomized, Placebo-controlled, Dose-ranging Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of AV7909 in Healthy Adults"},"statusModule":{"statusVerifiedDate":"2024-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-12"},"primaryCompletionDateStruct":{"date":"2012-05","type":"ACTUAL"},"completionDateStruct":{"date":"2012-06","type":"ACTUAL"},"studyFirstSubmitDate":"2010-12-17","studyFirstSubmitQcDate":"2010-12-20","studyFirstPostDateStruct":{"date":"2010-12-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-01-17","resultsFirstSubmitQcDate":"2014-08-01","resultsFirstPostDateStruct":{"date":"2014-08-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-03-14","lastUpdatePostDateStruct":{"date":"2024-03-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Emergent BioSolutions","class":"INDUSTRY"},"collaborators":[{"name":"National Institute of Allergy and Infectious Diseases (NIAID)","class":"NIH"},{"name":"Department of Health and Human Services","class":"FED"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity.","detailedDescription":"AV7909 is a new vaccine which is a combination of BioThrax (also called anthrax vaccine, adsorbed or AVA), a FDA-licensed vaccine, and CPG 7909. CPG 7909 is a synthetic short DNA sequence that has been shown to be an effective vaccine adjuvant, and one which increases the speed and the degree of the immune response to Protective Antigen (PA), the major vaccine antigen. In the current study, the safety, tolerability, and antibody response to PA will be studied for four different combinations of AVA and CPG 7909, and compared to both AVA and a saline placebo. All formulations of AV7909 have the same or less AVA than the licensed AVA vaccine and all have less CPG 7909 per dose than the formulation used in the first Phase I volunteer study of CPG 7909 combined with AVA."},"conditionsModule":{"conditions":["Bacillus Anthracis (Anthrax) Infection"],"keywords":["AVA","AV7909","Anthrax vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":105,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BioThrax","type":"ACTIVE_COMPARATOR","description":"BioThrax, 0.5 mL AVA per dose","interventionNames":["Biological: BioThrax"]},{"label":"AV7909 Formulation 1","type":"EXPERIMENTAL","description":"0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose","interventionNames":["Biological: AV7909 Formulation 1"]},{"label":"AV7909 Formulation 2","type":"EXPERIMENTAL","description":"0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose","interventionNames":["Biological: AV7909 Formulation 2"]},{"label":"AV7909 Formulation 3","type":"EXPERIMENTAL","description":"0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose","interventionNames":["Biological: AV7909 Formulation 3"]},{"label":"AV7909 Formulation 4","type":"EXPERIMENTAL","description":"0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose","interventionNames":["Biological: AV7909 Formulation 4"]},{"label":"Control","type":"PLACEBO_COMPARATOR","description":"Saline control","interventionNames":["Drug: Control"]}],"interventions":[{"type":"BIOLOGICAL","name":"BioThrax","description":"BioThrax","armGroupLabels":["BioThrax"],"otherNames":["Anthrax Vaccine Adsorbed (AVA)"]},{"type":"BIOLOGICAL","name":"AV7909 Formulation 1","description":"AV7909 Formulation 1","armGroupLabels":["AV7909 Formulation 1"]},{"type":"BIOLOGICAL","name":"AV7909 Formulation 2","description":"AV7909 Formulation 2","armGroupLabels":["AV7909 Formulation 2"]},{"type":"BIOLOGICAL","name":"AV7909 Formulation 3","description":"AV7909 Formulation 3","armGroupLabels":["AV7909 Formulation 3"]},{"type":"BIOLOGICAL","name":"AV7909 Formulation 4","description":"AV7909 Formulation 4","armGroupLabels":["AV7909 Formulation 4"]},{"type":"DRUG","name":"Control","description":"Saline control","armGroupLabels":["Control"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0)","description":"Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the first injection (Day 0).\n\nAll local reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of ISR was assessed using a grading scale based on FDA Guidance \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nSwelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:\n\n* Grade 0: none\n* Grade 1: \\<3 cm\n* Grade 2: 3 to 10 cm\n* Grade 3: \\>10 cm\n\nFor all other ISRs, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","timeFrame":"Days 0-6"},{"measure":"Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0)","description":"Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the first injection (Day 0).\n\nAll local reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of ISR was assessed using a grading scale based on FDA Guidance \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nSwelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:\n\n* Grade 0: none\n* Grade 1: \\<3 cm\n* Grade 2: 3 to 10 cm\n* Grade 3: \\>10 cm\n\nFor all other ISRs, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","timeFrame":"Days 0-6"},{"measure":"Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14)","description":"Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the second injection (Day 14).\n\nAll local reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of ISR was assessed using a grading scale based on FDA Guidance \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nSwelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:\n\n* Grade 0: none\n* Grade 1: \\<3 cm\n* Grade 2: 3 to 10 cm\n* Grade 3: \\>10 cm\n\nFor all other ISRs, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","timeFrame":"Days 14-20"},{"measure":"Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14)","description":"Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the second injection (Day 14).\n\nAll local reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of ISR was assessed using a grading scale based on FDA Guidance \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nSwelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:\n\n* Grade 0: none\n* Grade 1: \\<3 cm\n* Grade 2: 3 to 10 cm\n* Grade 3: \\>10 cm\n\nFor all other ISRs, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","timeFrame":"Days 14-20"},{"measure":"Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0)","description":"Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of systemic reactions was assessed using a grading scale based on FDA Guidance titled \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nToxicity grades for fever were derived from body temperature using the following scale:\n\n* Grade 0: \\<100°F\n* Grade 1: 100.0 - 101.5°F\n* Grade 2: 101.6 - 102.9°F ;\n* Grade 3: 103.0 - 105.0°F\n\nFor all other systemic reactions, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","timeFrame":"Days 0-6"},{"measure":"Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0)","description":"Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of systemic reactions was assessed using a grading scale based on FDA Guidance titled \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nToxicity grades for fever were derived from body temperature using the following scale:\n\n* Grade 0: \\<100°F\n* Grade 1: 100.0 - 101.5°F\n* Grade 2: 101.6 - 102.9°F ;\n* Grade 3: 103.0 - 105.0°F\n\nFor all other systemic reactions, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","timeFrame":"Days 0-6"},{"measure":"Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14)","description":"Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of systemic reactions was assessed using a grading scale based on FDA Guidance titled \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nToxicity grades for fever were derived from body temperature using the following scale:\n\n* Grade 0: \\<100°F\n* Grade 1: 100.0 - 101.5°F\n* Grade 2: 101.6 - 102.9°F ;\n* Grade 3: 103.0 - 105.0°F\n\nFor all other systemic reactions, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","timeFrame":"Days 14-20"},{"measure":"Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14)","description":"Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of systemic reactions was assessed using a grading scale based on FDA Guidance titled \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nToxicity grades for fever were derived from body temperature using the following scale:\n\n* Grade 0: \\<100°F\n* Grade 1: 100.0 - 101.5°F\n* Grade 2: 101.6 - 102.9°F ;\n* Grade 3: 103.0 - 105.0°F\n\nFor all other systemic reactions, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","timeFrame":"Days 14-20"},{"measure":"Incidence of Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events","description":"Hematology test included hemoglobin, hematocrit, white blood cell count, absolute lymphocyte count, absolute neutrophil count, absolute eosinophil count, and platelet count. Serum chemistry test included albumin, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, glucose, calcium, potassium, alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. Urinalysis included appearance, color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, and occult blood.\n\nHematology tests were done on Days 0, 1, 2, 7, 28, and 56. Serum chemistry tests and urinalysis were done on Days 0, 7, 28, and 56.","timeFrame":"Days 0-56"},{"measure":"Percentage of Subjects With Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events","description":"Hematology test included hemoglobin, hematocrit, white blood cell count, absolute lymphocyte count, absolute neutrophil count, absolute eosinophil count, and platelet count. Serum chemistry test included albumin, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, glucose, calcium, potassium, alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. Urinalysis included appearance, color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, and occult blood.\n\nHematology tests were done on Days 0, 1, 2, 7, 28, and 56. Serum chemistry tests and urinalysis were done on Days 0, 7, 28, and 56.","timeFrame":"Days 0-56"}],"secondaryOutcomes":[{"measure":"Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14.","description":"Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the lower limit of quantitation (LLOQ) of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.","timeFrame":"Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84."},{"measure":"Median Time to Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14.","description":"Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the LLOQ of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.","timeFrame":"Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84."},{"measure":"TNA NF50 GMTs Across Study Days After IM Administration of Investigational Product on Days 0 and 14.","description":"Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the LLOQ of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.","timeFrame":"Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be between 18 and 50 years of age, inclusive, at the time of enrollment.\n* Be in good health as determined by the investigator from medical history and a physical examination.\n* If a pre-menopausal female, must be using acceptable methods of birth control.\n* Have all hematology and chemistry parameters (measured at Screening) within the laboratory's normal range.\n* Have negative values for the following tests at Screening: Hepatitis C antibody, anti-Human Immunodeficiency Virus (Anti-HIV-1/-2/-O), and anti-Hepatitis B Core Antigen (Anti-HBc).\n* Be willing and capable of complying with all aspects of the protocol through completion of the required visits.\n* Have not donated blood in the preceding 8 weeks and are willing to not donate blood or plasma within 56 days after dosing.\n* Have adequate venous access for repeat phlebotomies.\n* Have read, understood and signed an informed consent form.\n\nExclusion Criteria:\n\nKey Exclusion Criteria:\n\n* A known anaphylactic response, severe systematic response, or serious hypersensitivity reaction to a prior immunization.\n* Prior immunization with anthrax vaccine, recombinant Protective Antigen (rPA) vaccine, or known exposure to anthrax organisms.\n* Have previously served in the military or plans to enlist in the military from Screening through Day 84.\n* Have participated in anthrax therapeutic or vaccine trials (monoclonal anti-protective antigen (PA) or anthrax immune globulins or anthrax vaccines).\n* Participation in any investigational clinical trial within 30 days preceding the Screening visit or planning to participate in a clinical trial requiring dosing through the Day 194 visit.\n* A history of drug or alcohol abuse within 12 months prior to Screening, or a positive result on a urine drug screen for amphetamines, barbiturates, benzodiazepines, cocaine, marijuana, methylenedioxymethamphetamine opiates, oxycodone, phencyclidine, propoxyphene, or tricyclic antidepressants.\n* Blood pressure greater than 145 millimeters of mercury (mmHg) systolic or 90 mmHg diastolic.\n* Past history of significant autoimmune disease such as rheumatoid arthritis, lupus erythematous, psoriasis, glomerulonephritis, or autoimmune thyroiditis.\n* A medical condition that, in the opinion of the Principal Investigator (PI), could adversely impact the subject's participation, safety, or conduct of the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Edward Bernton, MD","affiliation":"Emergent Biosolutions, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Miami Research Associates","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"North Carolina Clinical Research","city":"Raleigh","state":"North Carolina","zip":"27607","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"Jean Brown Research","city":"Salt Lake City","state":"Utah","zip":"84124","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}}]},"referencesModule":{"references":[{"pmid":"23701746","type":"RESULT","citation":"Hopkins RJ, Daczkowski NF, Kaptur PE, Muse D, Sheldon E, LaForce C, Sari S, Rudge TL, Bernton E. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. Vaccine. 2013 Jun 26;31(30):3051-8. doi: 10.1016/j.vaccine.2013.04.063. Epub 2013 May 10."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All 105 enrolled participants who met inclusion and exclusion criteria were dosed.","recruitmentDetails":"Participants were enrolled from 27 December 2010 to 08 March 2012 at three medical centers in the U.S.","groups":[{"id":"FG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"FG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL anthrax vaccine adsorbed \\[AVA\\] + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"FG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL anthrax vaccine adsorbed \\[AVA\\] + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"FG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL anthrax vaccine adsorbed \\[AVA\\] + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"FG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL anthrax vaccine adsorbed \\[AVA\\] + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"FG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"19"},{"groupId":"FG004","numSubjects":"18"},{"groupId":"FG005","numSubjects":"15"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"16"},{"groupId":"FG003","numSubjects":"18"},{"groupId":"FG004","numSubjects":"18"},{"groupId":"FG005","numSubjects":"15"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"BG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"BG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"BG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"BG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"BG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"105"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"5"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"100"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31.1","spread":"9.27"},{"groupId":"BG001","value":"32.8","spread":"10.31"},{"groupId":"BG002","value":"32.4","spread":"10.75"},{"groupId":"BG003","value":"32.6","spread":"9.15"},{"groupId":"BG004","value":"31.4","spread":"10.72"},{"groupId":"BG005","value":"31.4","spread":"8.61"},{"groupId":"BG006","value":"32.0","spread":"9.64"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"51"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"54"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"25"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"80"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"15"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"87"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"105"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80.06","spread":"18.799"},{"groupId":"BG001","value":"83.99","spread":"16.137"},{"groupId":"BG002","value":"75.75","spread":"12.232"},{"groupId":"BG003","value":"78.39","spread":"19.021"},{"groupId":"BG004","value":"76.24","spread":"15.649"},{"groupId":"BG005","value":"79.74","spread":"23.140"},{"groupId":"BG006","value":"79.03","spread":"17.487"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0)","description":"Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the first injection (Day 0).\n\nAll local reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of ISR was assessed using a grading scale based on FDA Guidance \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nSwelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:\n\n* Grade 0: none\n* Grade 1: \\<3 cm\n* Grade 2: 3 to 10 cm\n* Grade 3: \\>10 cm\n\nFor all other ISRs, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Days 0-6","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Any Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 1 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 2 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 1 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 2 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14.","description":"Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the lower limit of quantitation (LLOQ) of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.","populationDescription":"Participants 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"geometric mean titer","timeFrame":"Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG006","title":"Male BioThrax","description":"Male Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG007","title":"Male AV7909 Formulation 1","description":"Male Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG008","title":"Male AV7909 Formulation 2","description":"Male Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG009","title":"Male AV7909 Formulation 3","description":"Male Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG010","title":"Male AV7909 Formulation 4","description":"Male Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG011","title":"Male Saline","description":"Male Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG012","title":"Female BioThrax","description":"Female Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG013","title":"Female AV7909 Formulation 1","description":"Female Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG014","title":"Female AV7909 Formulation 2","description":"Female Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG015","title":"Female AV7909 Formulation 3","description":"Female Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG016","title":"Female AV7909 Formulation 4","description":"Female Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG017","title":"Female Saline","description":"Female Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"8"},{"groupId":"OG013","value":"8"},{"groupId":"OG014","value":"8"},{"groupId":"OG015","value":"10"},{"groupId":"OG016","value":"9"},{"groupId":"OG017","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","lowerLimit":"0.07","upperLimit":"0.30"},{"groupId":"OG001","value":"3.40","lowerLimit":"2.33","upperLimit":"4.94"},{"groupId":"OG002","value":"4.02","lowerLimit":"2.46","upperLimit":"6.57"},{"groupId":"OG003","value":"2.81","lowerLimit":"1.50","upperLimit":"5.26"},{"groupId":"OG004","value":"1.93","lowerLimit":"0.85","upperLimit":"4.43"},{"groupId":"OG005","value":"0.04","lowerLimit":"0.02","upperLimit":"0.08"},{"groupId":"OG006","value":"0.19","lowerLimit":"0.06","upperLimit":"0.62"},{"groupId":"OG007","value":"3.44","lowerLimit":"1.84","upperLimit":"6.43"},{"groupId":"OG008","value":"4.19","lowerLimit":"2.19","upperLimit":"7.98"},{"groupId":"OG009","value":"2.99","lowerLimit":"1.32","upperLimit":"6.78"},{"groupId":"OG010","value":"2.45","lowerLimit":"0.54","upperLimit":"11.12"},{"groupId":"OG011","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were equal and below the lower limit of quantitation"},{"groupId":"OG012","value":"0.11","lowerLimit":"0.04","upperLimit":"0.36"},{"groupId":"OG013","value":"3.35","lowerLimit":"1.91","upperLimit":"5.88"},{"groupId":"OG014","value":"3.87","lowerLimit":"1.54","upperLimit":"9.71"},{"groupId":"OG015","value":"2.68","lowerLimit":"0.92","upperLimit":"7.80"},{"groupId":"OG016","value":"1.53","lowerLimit":"0.53","upperLimit":"4.39"},{"groupId":"OG017","value":"0.06","lowerLimit":"0.01","upperLimit":"0.21"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0)","description":"Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the first injection (Day 0).\n\nAll local reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of ISR was assessed using a grading scale based on FDA Guidance \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nSwelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:\n\n* Grade 0: none\n* Grade 1: \\<3 cm\n* Grade 2: 3 to 10 cm\n* Grade 3: \\>10 cm\n\nFor all other ISRs, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Days 0-6","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Any Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"61.1"},{"groupId":"OG001","value":"94.4"},{"groupId":"OG002","value":"76.5"},{"groupId":"OG003","value":"63.2"},{"groupId":"OG004","value":"88.9"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 1 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"64.7"},{"groupId":"OG003","value":"31.6"},{"groupId":"OG004","value":"61.1"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 2 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"33.3"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"31.6"},{"groupId":"OG004","value":"27.8"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"22.2"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"55.6"},{"groupId":"OG001","value":"88.9"},{"groupId":"OG002","value":"64.7"},{"groupId":"OG003","value":"57.9"},{"groupId":"OG004","value":"72.2"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 1 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"72.2"},{"groupId":"OG002","value":"58.8"},{"groupId":"OG003","value":"52.6"},{"groupId":"OG004","value":"61.1"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 2 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"27.8"},{"groupId":"OG001","value":"77.8"},{"groupId":"OG002","value":"70.6"},{"groupId":"OG003","value":"42.1"},{"groupId":"OG004","value":"61.1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"66.7"},{"groupId":"OG002","value":"70.6"},{"groupId":"OG003","value":"36.8"},{"groupId":"OG004","value":"44.4"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"16.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"44.4"},{"groupId":"OG001","value":"72.2"},{"groupId":"OG002","value":"47.1"},{"groupId":"OG003","value":"47.4"},{"groupId":"OG004","value":"55.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"38.9"},{"groupId":"OG001","value":"44.4"},{"groupId":"OG002","value":"41.2"},{"groupId":"OG003","value":"21.1"},{"groupId":"OG004","value":"33.3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"26.3"},{"groupId":"OG004","value":"22.2"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14)","description":"Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the second injection (Day 14).\n\nAll local reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of ISR was assessed using a grading scale based on FDA Guidance \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nSwelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:\n\n* Grade 0: none\n* Grade 1: \\<3 cm\n* Grade 2: 3 to 10 cm\n* Grade 3: \\>10 cm\n\nFor all other ISRs, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Days 14-20","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Any Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Redness","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Redness","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14)","description":"Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the second injection (Day 14).\n\nAll local reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of ISR was assessed using a grading scale based on FDA Guidance \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nSwelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:\n\n* Grade 0: none\n* Grade 1: \\<3 cm\n* Grade 2: 3 to 10 cm\n* Grade 3: \\>10 cm\n\nFor all other ISRs, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Days 14-20","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Any Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"61.1"},{"groupId":"OG001","value":"88.9"},{"groupId":"OG002","value":"70.6"},{"groupId":"OG003","value":"57.9"},{"groupId":"OG004","value":"72.2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"44.4"},{"groupId":"OG002","value":"52.9"},{"groupId":"OG003","value":"31.6"},{"groupId":"OG004","value":"38.9"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"33.3"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"15.8"},{"groupId":"OG004","value":"33.3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Redness","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"15.8"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Redness","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Redness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"22.2"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"61.1"},{"groupId":"OG001","value":"72.2"},{"groupId":"OG002","value":"64.7"},{"groupId":"OG003","value":"52.6"},{"groupId":"OG004","value":"66.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"44.4"},{"groupId":"OG001","value":"44.14"},{"groupId":"OG002","value":"64.7"},{"groupId":"OG003","value":"42.1"},{"groupId":"OG004","value":"50.0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"16.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"72.2"},{"groupId":"OG002","value":"58.8"},{"groupId":"OG003","value":"42.1"},{"groupId":"OG004","value":"33.3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"55.6"},{"groupId":"OG002","value":"58.8"},{"groupId":"OG003","value":"31.6"},{"groupId":"OG004","value":"16.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"16.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Injection Site Pain","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Injection Site Itching","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"44.4"},{"groupId":"OG001","value":"61.1"},{"groupId":"OG002","value":"41.2"},{"groupId":"OG003","value":"42.1"},{"groupId":"OG004","value":"44.4"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"33.3"},{"groupId":"OG002","value":"35.3"},{"groupId":"OG003","value":"21.1"},{"groupId":"OG004","value":"16.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"22.2"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"15.8"},{"groupId":"OG004","value":"27.8"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Arm Motion Limitation","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0)","description":"Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of systemic reactions was assessed using a grading scale based on FDA Guidance titled \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nToxicity grades for fever were derived from body temperature using the following scale:\n\n* Grade 0: \\<100°F\n* Grade 1: 100.0 - 101.5°F\n* Grade 2: 101.6 - 102.9°F ;\n* Grade 3: 103.0 - 105.0°F\n\nFor all other systemic reactions, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Days 0-6","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Any Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"5"}]}]},{"title":"Grade 1 Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"}]}]},{"title":"Grade 2 Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 3 Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"}]}]},{"title":"Grade 1 Fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"}]}]},{"title":"Any Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}]}]},{"title":"Grade 1 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Grade 2 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Grade 1 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 2 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"Any Headache","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"}]}]},{"title":"Grade 1 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 2 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 3 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Grade 1 Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 2 Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0)","description":"Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of systemic reactions was assessed using a grading scale based on FDA Guidance titled \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nToxicity grades for fever were derived from body temperature using the following scale:\n\n* Grade 0: \\<100°F\n* Grade 1: 100.0 - 101.5°F\n* Grade 2: 101.6 - 102.9°F ;\n* Grade 3: 103.0 - 105.0°F\n\nFor all other systemic reactions, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0-6","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Any Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"55.6"},{"groupId":"OG001","value":"66.7"},{"groupId":"OG002","value":"41.2"},{"groupId":"OG003","value":"15.8"},{"groupId":"OG004","value":"38.9"},{"groupId":"OG005","value":"33.3"}]}]},{"title":"Grade 1 Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"44.4"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"29.4"},{"groupId":"OG003","value":"15.8"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"26.7"}]}]},{"title":"Grade 2 Systemic Reactions","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"38.9"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"22.2"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 3 Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"13.3"}]}]},{"title":"Grade 1 Fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"13.3"}]}]},{"title":"Any Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"15.8"},{"groupId":"OG004","value":"22.2"},{"groupId":"OG005","value":"13.3"}]}]},{"title":"Grade 1 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"27.8"},{"groupId":"OG001","value":"22.2"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"15.8"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"13.3"}]}]},{"title":"Grade 2 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"44.4"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"13.3"}]}]},{"title":"Grade 1 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"33.3"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 2 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Any Headache","categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"61.1"},{"groupId":"OG002","value":"29.4"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"27.8"},{"groupId":"OG005","value":"13.3"}]}]},{"title":"Grade 1 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"22.2"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 2 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8.9"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"16.47"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 3 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"22.2"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"13.3"}]}]},{"title":"Grade 1 Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 2 Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6.7"}]}]}]},{"type":"PRIMARY","title":"Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14)","description":"Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of systemic reactions was assessed using a grading scale based on FDA Guidance titled \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nToxicity grades for fever were derived from body temperature using the following scale:\n\n* Grade 0: \\<100°F\n* Grade 1: 100.0 - 101.5°F\n* Grade 2: 101.6 - 102.9°F ;\n* Grade 3: 103.0 - 105.0°F\n\nFor all other systemic reactions, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Days 14-20","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Any Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"2"}]}]},{"title":"Grade 1 Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 2 Systemic Reactions","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 3 Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 1 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 2 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Headache","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 1 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"}]}]},{"title":"Grade 3 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14)","description":"Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.\n\nSeverity of systemic reactions was assessed using a grading scale based on FDA Guidance titled \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.\"\n\nToxicity grades for fever were derived from body temperature using the following scale:\n\n* Grade 0: \\<100°F\n* Grade 1: 100.0 - 101.5°F\n* Grade 2: 101.6 - 102.9°F ;\n* Grade 3: 103.0 - 105.0°F\n\nFor all other systemic reactions, the following scale was used:\n\n* Grade 0: not present\n* Grade 1: present with no limitation of activity\n* Grade 2: interfering with daily activities or requiring non-narcotic treatment\n* Grade 3: preventing normal daily activities or requiring narcotic analgesia","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 14-20","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Any Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"38.9"},{"groupId":"OG001","value":"77.8"},{"groupId":"OG002","value":"41.2"},{"groupId":"OG003","value":"21.1"},{"groupId":"OG004","value":"50.0"},{"groupId":"OG005","value":"13.3"}]}]},{"title":"Grade 1 Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"44.14"},{"groupId":"OG002","value":"35.3"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"22.2"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 2 Systemic Reactions","categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"27.8"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 3 Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"44.4"},{"groupId":"OG002","value":"23.5"},{"groupId":"OG003","value":"15.8"},{"groupId":"OG004","value":"38.9"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 1 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"22.2"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 2 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"16.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"27.8"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"38.9"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"11.8"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"22.2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"16.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 3 Muscle Ache","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Headache","categories":[{"measurements":[{"groupId":"OG000","value":"27.8"},{"groupId":"OG001","value":"38.9"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"15.8"},{"groupId":"OG004","value":"38.9"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 1 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"16.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"22.2"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Grade 3 Headache","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Any Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"16.7"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 1 Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"11.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Grade 2 Nausea / GI Upset","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Incidence of Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events","description":"Hematology test included hemoglobin, hematocrit, white blood cell count, absolute lymphocyte count, absolute neutrophil count, absolute eosinophil count, and platelet count. Serum chemistry test included albumin, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, glucose, calcium, potassium, alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. Urinalysis included appearance, color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, and occult blood.\n\nHematology tests were done on Days 0, 1, 2, 7, 28, and 56. Serum chemistry tests and urinalysis were done on Days 0, 7, 28, and 56.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Days 0-56","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Alanine aminotransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]}]},{"title":"Aspartate aminotransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Blood creatinine increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Blood lactate dehydrogenase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"Blood urea increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Hepatic enzyme increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"Hyperkalemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Hypoglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Hypokalemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Hypomagnesemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Lymphocyte count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}]}]},{"title":"Neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Neutrophil count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Protein urine","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]}]},{"title":"Red blood cells urine positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"White blood cell count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}]},{"title":"White blood cell count increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"White blood cells urine positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events","description":"Hematology test included hemoglobin, hematocrit, white blood cell count, absolute lymphocyte count, absolute neutrophil count, absolute eosinophil count, and platelet count. Serum chemistry test included albumin, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, glucose, calcium, potassium, alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. Urinalysis included appearance, color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, and occult blood.\n\nHematology tests were done on Days 0, 1, 2, 7, 28, and 56. Serum chemistry tests and urinalysis were done on Days 0, 7, 28, and 56.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0-56","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14"},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14"},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Alanine aminotransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Aspartate aminotransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Blood creatinine increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Blood lactate dehydrogenase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Blood urea increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Hepatic enzyme increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Hyperkalemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Hypoglycemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"10.5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Hypokalemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Hypomagnesemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Lymphocyte count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"33.3"},{"groupId":"OG002","value":"17.6"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"22.2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Neutrophil count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Protein urine","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5.3"},{"groupId":"OG004","value":"5.6"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"Red blood cells urine positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"White blood cell count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"27.8"},{"groupId":"OG002","value":"23.5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"11.1"},{"groupId":"OG005","value":"6.7"}]}]},{"title":"White blood cell count increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"White blood cells urine positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.9"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Median Time to Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14.","description":"Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the LLOQ of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.","populationDescription":"Participants 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"days","timeFrame":"Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG006","title":"Male BioThrax","description":"Male Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG007","title":"Male AV7909 Formulation 1","description":"Male Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG008","title":"Male AV7909 Formulation 2","description":"Male Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG009","title":"Male AV7909 Formulation 3","description":"Male Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG010","title":"Male AV7909 Formulation 4","description":"Male Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG011","title":"Male Saline","description":"Male participants between 18 and 50 years of age who received two doses of saline; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG012","title":"Female BioThrax","description":"Female Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG013","title":"Female AV7909 Formulation 1","description":"Female Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG014","title":"Female AV7909 Formulation 2","description":"Female Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG015","title":"Female AV7909 Formulation 3","description":"Female Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG016","title":"Female AV7909 Formulation 4","description":"Female Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG017","title":"Female Saline","description":"Female participants between 18 and 50 years of age who received two doses of saline; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"8"},{"groupId":"OG013","value":"8"},{"groupId":"OG014","value":"8"},{"groupId":"OG015","value":"10"},{"groupId":"OG016","value":"9"},{"groupId":"OG017","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","lowerLimit":"7","upperLimit":"42"},{"groupId":"OG001","value":"29.0","lowerLimit":"21","upperLimit":"42"},{"groupId":"OG002","value":"28.0","lowerLimit":"22","upperLimit":"35"},{"groupId":"OG003","value":"28.5","lowerLimit":"27","upperLimit":"42"},{"groupId":"OG004","value":"29.0","lowerLimit":"7","upperLimit":"42"},{"groupId":"OG005","value":"7.0","lowerLimit":"6","upperLimit":"70"},{"groupId":"OG006","value":"28.0","lowerLimit":"7","upperLimit":"35"},{"groupId":"OG007","value":"28.0","lowerLimit":"21","upperLimit":"42"},{"groupId":"OG008","value":"28.0","lowerLimit":"22","upperLimit":"35"},{"groupId":"OG009","value":"28.0","lowerLimit":"28","upperLimit":"39"},{"groupId":"OG010","value":"28.0","lowerLimit":"7","upperLimit":"35"},{"groupId":"OG011","value":"7.0","lowerLimit":"7","upperLimit":"8"},{"groupId":"OG012","value":"18.5","lowerLimit":"7","upperLimit":"42"},{"groupId":"OG013","value":"32.0","lowerLimit":"28","upperLimit":"36"},{"groupId":"OG014","value":"28.0","lowerLimit":"22","upperLimit":"30"},{"groupId":"OG015","value":"29.0","lowerLimit":"27","upperLimit":"42"},{"groupId":"OG016","value":"35.0","lowerLimit":"21","upperLimit":"42"},{"groupId":"OG017","value":"7.0","lowerLimit":"6","upperLimit":"70"}]}]}]},{"type":"SECONDARY","title":"TNA NF50 GMTs Across Study Days After IM Administration of Investigational Product on Days 0 and 14.","description":"Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the LLOQ of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.","populationDescription":"Participants 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100).","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"geometric mean titer","timeFrame":"Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.","groups":[{"id":"OG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."},{"id":"OG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline; total volume 0.5 mL) IM on Days 0 and 14 Antibody titers were assessed in the immunogenicity population, which included subjects who received both vaccinations, had immunogenicity data within the allowable window, and had no protocol violations that could affect TNA values (n=100)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Day 0","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG001","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG002","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG003","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG004","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG005","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"}]}]},{"title":"Day 7","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG001","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG002","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG003","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG004","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG005","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"}]}]},{"title":"Day 14","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG001","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"},{"groupId":"OG002","value":"0.04","lowerLimit":"0.03","upperLimit":"0.05"},{"groupId":"OG003","value":"0.04","lowerLimit":"0.03","upperLimit":"0.06"},{"groupId":"OG004","value":"0.04","lowerLimit":"0.03","upperLimit":"0.05"},{"groupId":"OG005","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"}]}]},{"title":"Day 21","categories":[{"measurements":[{"groupId":"OG000","value":"0.04","lowerLimit":"0.0276","upperLimit":"0.0651"},{"groupId":"OG001","value":"1.27","lowerLimit":"0.78","upperLimit":"2.07"},{"groupId":"OG002","value":"0.77","lowerLimit":"0.32","upperLimit":"1.83"},{"groupId":"OG003","value":"0.90","lowerLimit":"0.46","upperLimit":"1.75"},{"groupId":"OG004","value":"0.44","lowerLimit":"0.17","upperLimit":"1.10"},{"groupId":"OG005","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"}]}]},{"title":"Day 28","categories":[{"measurements":[{"groupId":"OG000","value":"0.13","lowerLimit":"0.06","upperLimit":"0.28"},{"groupId":"OG001","value":"3.05","lowerLimit":"2.07","upperLimit":"4.52"},{"groupId":"OG002","value":"3.85","lowerLimit":"2.40","upperLimit":"6.20"},{"groupId":"OG003","value":"2.54","lowerLimit":"1.26","upperLimit":"5.12"},{"groupId":"OG004","value":"1.73","lowerLimit":"0.77","upperLimit":"3.89"},{"groupId":"OG005","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"}]}]},{"title":"Day 35","categories":[{"measurements":[{"groupId":"OG000","value":"0.15","lowerLimit":"0.07","upperLimit":"0.32"},{"groupId":"OG001","value":"2.61","lowerLimit":"1.82","upperLimit":"3.75"},{"groupId":"OG002","value":"2.89","lowerLimit":"1.80","upperLimit":"4.61"},{"groupId":"OG003","value":"2.23","lowerLimit":"1.11","upperLimit":"4.45"},{"groupId":"OG004","value":"1.56","lowerLimit":"0.68","upperLimit":"3.59"},{"groupId":"OG005","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"}]}]},{"title":"Day 42","categories":[{"measurements":[{"groupId":"OG000","value":"0.13","lowerLimit":"0.07","upperLimit":"0.24"},{"groupId":"OG001","value":"2.01","lowerLimit":"1.37","upperLimit":"2.95"},{"groupId":"OG002","value":"2.03","lowerLimit":"1.32","upperLimit":"3.12"},{"groupId":"OG003","value":"1.78","lowerLimit":"0.95","upperLimit":"3.34"},{"groupId":"OG004","value":"1.17","lowerLimit":"0.53","upperLimit":"2.59"},{"groupId":"OG005","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"}]}]},{"title":"Day 56","categories":[{"measurements":[{"groupId":"OG000","value":"0.09","lowerLimit":"0.05","upperLimit":"0.16"},{"groupId":"OG001","value":"1.18","lowerLimit":"0.81","upperLimit":"1.71"},{"groupId":"OG002","value":"1.52","lowerLimit":"0.97","upperLimit":"2.36"},{"groupId":"OG003","value":"1.09","lowerLimit":"0.58","upperLimit":"2.07"},{"groupId":"OG004","value":"0.76","lowerLimit":"0.37","upperLimit":"1.61"},{"groupId":"OG005","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"}]}]},{"title":"Day 70","categories":[{"measurements":[{"groupId":"OG000","value":"0.06","lowerLimit":"0.04","upperLimit":"0.10"},{"groupId":"OG001","value":"0.85","lowerLimit":"0.56","upperLimit":"1.29"},{"groupId":"OG002","value":"0.91","lowerLimit":"0.58","upperLimit":"1.41"},{"groupId":"OG003","value":"0.71","lowerLimit":"0.40","upperLimit":"1.25"},{"groupId":"OG004","value":"0.55","lowerLimit":"0.26","upperLimit":"1.16"},{"groupId":"OG005","value":"0.04","lowerLimit":"0.02","upperLimit":"0.08"}]}]},{"title":"Day 84","categories":[{"measurements":[{"groupId":"OG000","value":"0.05","lowerLimit":"0.04","upperLimit":"0.08"},{"groupId":"OG001","value":"0.67","lowerLimit":"0.42","upperLimit":"1.08"},{"groupId":"OG002","value":"0.69","lowerLimit":"0.44","upperLimit":"1.10"},{"groupId":"OG003","value":"0.55","lowerLimit":"0.32","upperLimit":"0.94"},{"groupId":"OG004","value":"0.39","lowerLimit":"0.20","upperLimit":"0.77"},{"groupId":"OG005","value":"0.03","lowerLimit":"NA","upperLimit":"NA","comment":"All values were below the LLOQ for the assay"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Serious adverse event data were collected at study visits from Day 0 to Day 84 and during safety follow-up telephone calls at 6 and 12 months.","description":"Serious adverse events were coded using Medical Dictionary for Regulatory Activities (MedDRA®) Version 14.0.\n\nSeverity of laboratory toxicities were assessed using the Toxicity Grading Scale in the protocol.\n\nFor determination of Other Adverse Events frequency, all study Arms were combined.","eventGroups":[{"id":"EG000","title":"BioThrax","description":"Participants between 18 and 50 years of age who received two doses of BioThrax (0.5 mL) intramuscularly (IM) on Days 0 and 14","seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":16,"otherNumAtRisk":18},{"id":"EG001","title":"AV7909 Formulation 1","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14","seriousNumAffected":1,"seriousNumAtRisk":18,"otherNumAffected":18,"otherNumAtRisk":18},{"id":"EG002","title":"AV7909 Formulation 2","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14","seriousNumAffected":1,"seriousNumAtRisk":17,"otherNumAffected":14,"otherNumAtRisk":17},{"id":"EG003","title":"AV7909 Formulation 3","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14","seriousNumAffected":0,"seriousNumAtRisk":19,"otherNumAffected":14,"otherNumAtRisk":19},{"id":"EG004","title":"AV7909 Formulation 4","description":"Participants between 18 and 50 years of age who received two doses of AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909; total volume 0.5 mL) IM on Days 0 and 14","seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":18,"otherNumAtRisk":18},{"id":"EG005","title":"Saline","description":"Participants between 18 and 50 years of age who received two doses of saline placebo (0.5 mL) IM on Days 0 and 14","seriousNumAffected":1,"seriousNumAtRisk":15,"otherNumAffected":9,"otherNumAtRisk":15}],"seriousEvents":[{"term":"Elevated hepatic enzymes","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Elevated hepatic enzymes (Grade 4 elevated Alanine aminotransferase \\[ALT\\], Grade 3 elevated Aspartate aminotransferase \\[AST\\]) on Day 28 was attributed to an acute Epstein-Barr infection (unrelated to vaccination).","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Melanocytic Naevus","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Glioblastoma multiforme was reported during 6-month safety follow-up telephone call. The event was assessed as unrelated to vaccination.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Death","organSystem":"Social circumstances","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Road traffic accident resulting in death was reported during 12-month safety follow-up telephone call. The event was assessed as unrelated to vaccination.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]}],"otherEvents":[{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":18},{"groupId":"EG001","numEvents":21,"numAffected":13,"numAtRisk":18},{"groupId":"EG002","numEvents":14,"numAffected":6,"numAtRisk":17},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":19},{"groupId":"EG004","numEvents":13,"numAffected":9,"numAtRisk":18},{"groupId":"EG005","numEvents":4,"numAffected":3,"numAtRisk":15}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":6,"numAtRisk":18},{"groupId":"EG001","numEvents":20,"numAffected":11,"numAtRisk":18},{"groupId":"EG002","numEvents":9,"numAffected":5,"numAtRisk":17},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":19},{"groupId":"EG004","numEvents":17,"numAffected":10,"numAtRisk":18},{"groupId":"EG005","numEvents":6,"numAffected":2,"numAtRisk":15}]},{"term":"Injection Site Reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":15,"numAtRisk":18},{"groupId":"EG001","numEvents":36,"numAffected":18,"numAtRisk":18},{"groupId":"EG002","numEvents":27,"numAffected":14,"numAtRisk":17},{"groupId":"EG003","numEvents":24,"numAffected":14,"numAtRisk":19},{"groupId":"EG004","numEvents":32,"numAffected":16,"numAtRisk":18},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Lymphocyte Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":18},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":17},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":18},{"groupId":"EG001","numEvents":21,"numAffected":10,"numAtRisk":18},{"groupId":"EG002","numEvents":11,"numAffected":4,"numAtRisk":17},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG004","numEvents":14,"numAffected":10,"numAtRisk":18},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":15}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG001","numEvents":14,"numAffected":6,"numAtRisk":18},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":17},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":17},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":18},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":17},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":19},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":15}]},{"term":"White Blood Cell Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":18},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":18},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Rotator Cuff Syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Facial Bones Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Blepharospasm","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Jaw Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Sternal Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Traumatic Lung Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (14.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Blood creatine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Hyperkalemia","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hypoglycemia","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hypokalemia","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hypomagnesemia","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Neutropenia","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Protein urine","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Red blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"White blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor is responsible for public disclosure of study data. Any proposed publication is subject to review agreed between National Institute of Allergy and Infectious Disease (NIAID) and Emergent; between Emergent and the contract research organizations (CROs)/vendors; and between the CROs and the site Principal Investigator. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld."},"pointOfContact":{"title":"Dr. Robert Hopkins","organization":"Emergent BioSolutions","email":"hopkinsr@ebsi.com","phone":"(301) 944-0136"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D000881","term":"Anthrax"},{"id":"D007239","term":"Infections"}],"ancestors":[{"id":"D016863","term":"Bacillaceae Infections"},{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"}]},"interventionBrowseModule":{"meshes":[{"id":"C493276","term":"Biothrax"},{"id":"D022122","term":"Anthrax Vaccines"}],"ancestors":[{"id":"D001428","term":"Bacterial Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}